Stoke Therapeutics (STOK) Total Non-Current Liabilities (2018 - 2026)

Stoke Therapeutics' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $7.6 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 37.39% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (down 37.39% YoY), while the FY2025 annual figure was $8.1 million, up 226.96% from the prior year.
• Total Non-Current Liabilities was $7.6 million for Q1 2026 at Stoke Therapeutics, down from $8.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $53.1 million in Q1 2022 to a low of $2.5 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $27.1 million across 5 years, with a median of $29.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities surged 15832.73% in 2022, then tumbled 93.47% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $39.8 million in 2022, then decreased by 4.69% to $38.0 million in 2023, then sank by 93.47% to $2.5 million in 2024, then surged by 226.96% to $8.1 million in 2025, then retreated by 6.27% to $7.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $7.6 million (Q1 2026), $8.1 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.